These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

519 related items for PubMed ID: 25248470

  • 1. Trimodality bladder-sparing approach without neoadjuvant chemotherapy for node-negative localized muscle-invasive urinary bladder cancer resulted in comparable cystectomy-free survival.
    Lee CY, Yang KL, Ko HL, Huang RY, Tsai PP, Chen MT, Lin YC, Hwang TI, Juang GD, Chi KH.
    Radiat Oncol; 2014 Sep 24; 9():213. PubMed ID: 25248470
    [Abstract] [Full Text] [Related]

  • 2. Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer.
    Jiang DM, Jiang H, Chung PWM, Zlotta AR, Fleshner NE, Bristow RG, Berlin A, Kulkarni GS, Alimohamed NS, Lo G, Sridhar SS.
    Clin Genitourin Cancer; 2019 Feb 24; 17(1):38-45. PubMed ID: 30686350
    [Abstract] [Full Text] [Related]

  • 3. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial.
    Mitin T, Hunt D, Shipley WU, Kaufman DS, Uzzo R, Wu CL, Buyyounouski MK, Sandler H, Zietman AL.
    Lancet Oncol; 2013 Aug 24; 14(9):863-72. PubMed ID: 23823157
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
    George L, Bladou F, Bardou VJ, Gravis G, Tallet A, Alzieu C, Serment G, Salem N.
    Urology; 2004 Sep 24; 64(3):488-93. PubMed ID: 15351577
    [Abstract] [Full Text] [Related]

  • 6. Long-term results of two prospective bladder-sparing trimodality approaches for invasive bladder cancer: neoadjuvant chemotherapy and concurrent radio-chemotherapy.
    Zapatero A, Martin De Vidales C, Arellano R, Ibañez Y, Bocardo G, Perez M, Rabadan M, García Vicente F, Cruz Conde JA, Olivier C.
    Urology; 2012 Nov 24; 80(5):1056-62. PubMed ID: 22999456
    [Abstract] [Full Text] [Related]

  • 7. Initial results of retrospective study: preoperative transurethral excision plus chemotherapy and radiation therapy and trial of bladder preservation.
    Gamal El-Deen HS.
    J Egypt Natl Canc Inst; 2007 Jun 24; 19(2):133-46. PubMed ID: 19034344
    [Abstract] [Full Text] [Related]

  • 8. Initial results of bladder preserving approach by chemo-radiotherapy in patients with muscle invading transitional cell carcinoma.
    Aboziada MA, Hamza HM, Abdlrahem AM.
    J Egypt Natl Canc Inst; 2009 Jun 24; 21(2):167-74. PubMed ID: 21057568
    [Abstract] [Full Text] [Related]

  • 9. Neoadjuvant Cisplatin-Based Chemotherapy Followed by Selective Bladder Preservation Chemoradiotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder: Post Hoc Analysis of Two Prospective Studies.
    Cho SW, Lim SH, Kwon GY, Kim CK, Park W, Pyo H, Chung JH, Song W, Sung HH, Jeong BC, Park SH.
    Cancer Res Treat; 2024 Jul 24; 56(3):893-897. PubMed ID: 38374699
    [Abstract] [Full Text] [Related]

  • 10. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.
    Efstathiou JA, Spiegel DY, Shipley WU, Heney NM, Kaufman DS, Niemierko A, Coen JJ, Skowronski RY, Paly JJ, McGovern FJ, Zietman AL.
    Eur Urol; 2012 Apr 24; 61(4):705-11. PubMed ID: 22101114
    [Abstract] [Full Text] [Related]

  • 11. Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer: single-institution experience.
    Tunio MA, Hashmi A, Qayyum A, Mohsin R, Zaeem A.
    Int J Radiat Oncol Biol Phys; 2012 Mar 01; 82(3):e457-62. PubMed ID: 21945107
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer.
    Cahn DB, Handorf EA, Ghiraldi EM, Ristau BT, Geynisman DM, Churilla TM, Horwitz EM, Sobczak ML, Chen DYT, Viterbo R, Greenberg RE, Kutikov A, Uzzo RG, Smaldone MC.
    Cancer; 2017 Nov 15; 123(22):4337-4345. PubMed ID: 28743162
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Selective organ preservation in muscle-invasive bladder cancer: review of the literature.
    Khosravi-Shahi P, Cabezón-Gutiérrez L.
    Surg Oncol; 2012 Mar 15; 21(1):e17-22. PubMed ID: 22088598
    [Abstract] [Full Text] [Related]

  • 19. Concurrent cisplatin, 5-fluorouracil, leucovorin, and radiotherapy for invasive bladder cancer.
    Chen WC, Liaw CC, Chuang CK, Chen MF, Chen CS, Lin PY, Chang PL, Chu SH, Wu CT, Hong JH.
    Int J Radiat Oncol Biol Phys; 2003 Jul 01; 56(3):726-33. PubMed ID: 12788178
    [Abstract] [Full Text] [Related]

  • 20. An Effective and Well Tolerated Strategy of Bladder Preservation Therapy in Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer.
    Feng YH, Shen KH, Huang KH, Tzeng WS, Li CF, Lin KL.
    Clin Genitourin Cancer; 2016 Feb 01; 14(1):e67-74. PubMed ID: 26428609
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.